Plus Therapeutics (NASDAQ:PSTV) Issues Earnings Results

Plus Therapeutics (NASDAQ:PSTV) issued its quarterly earnings data on Thursday. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16), Zacks reports. The business had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.19 million.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock traded down $0.35 during trading on Friday, hitting $1.17. The company’s stock had a trading volume of 2,155,444 shares, compared to its average volume of 3,920,618. Plus Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.67. The company has a market capitalization of $6.90 million, a PE ratio of -0.46 and a beta of 0.73. The company has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $1.24.

Analyst Upgrades and Downgrades

PSTV has been the topic of several research analyst reports. Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. HC Wainwright reduced their target price on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating on the stock in a report on Friday. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Plus Therapeutics in a research report on Friday.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.